Iterum Therapeutics plc (ITRM)
Largest Insider Buys in Sector
ITRM Stock Price History Chart
ITRM Stock Performance
About Iterum Therapeutics plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Activity of Iterum Therapeutics plc
Over the last 12 months, insiders at Iterum Therapeutics plc have bought $94,132 and sold $0 worth of Iterum Therapeutics plc stock.
On average, over the past 5 years, insiders at Iterum Therapeutics plc have bought $49,999 and sold $12.8M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Dunne Michael W. (director) — $94,132.
The last purchase of 25,000 shares for transaction amount of $35,000 was made by Dunne Michael W. (director) on 2023‑12‑22.
List of Insider Buy and Sell Transactions, Iterum Therapeutics plc
| 2023-12-22 | director | 25,000 0.1716% | $1.40 | $35,000 | +1.07% | |||
| 2023-12-18 | director | 10,000 0.0794% | $1.84 | $18,442 | -18.75% | |||
| 2023-11-22 | director | 20,000 0.1507% | $2.03 | $40,690 | -29.81% | |||
| 2023-11-20 | Chief Executive Officer | 10,000 0.0872% | $1.59 | $15,863 | +4.66% | |||
| 2022-12-02 | Sale | Chief Medical Officer | 3,365 0.0261% | $1.32 | $4,442 | -23.02% | ||
| 2022-03-14 | Sale | Chief Financial Officer | 63,340 0.029% | $0.31 | $19,635 | -62.16% | ||
| 2022-03-11 | Sale | Chief Financial Officer | 47,132 0.0261% | $0.38 | $17,910 | -61.07% | ||
| 2021-02-12 | Sale | 10 percent owner | 10.62M 8.7758% | $2.27 | $24.11M | -69.11% | ||
| 2021-02-11 | Sale | 10 percent owner | 10M 9.0673% | $2.59 | $25.9M | -70.30% | ||
| 2021-01-26 | Sale | President & CEO | 170,890 0.077% | $0.86 | $147,820 | -49.75% | ||
| 2021-01-26 | Sale | director | 33,143 0.0299% | $1.73 | $57,337 | -49.75% | ||
| 2021-01-26 | Sale | Chief Financial Officer | 33,868 0.0305% | $1.73 | $58,592 | -49.75% | ||
| 2020-10-27 | Chief Scientific Officer | 123,080 0.3428% | $0.33 | $40,001 | +124.28% | |||
| 2020-09-30 | Sale | Chief Financial Officer | 112,260 0.3651% | $0.82 | $92,053 | +5.71% | ||
| 2020-06-02 | Sale | 10 percent owner | 800,000 2.5418% | $0.80 | $642,960 | -32.10% | ||
| 2020-06-01 | Sale | 10 percent owner | 200,000 0.6371% | $0.85 | $169,120 | -35.29% | ||
| 2018-11-30 | director | 20,000 0.1148% | $3.14 | $62,887 | +2.19% | |||
| 2018-10-30 | director | 116,000 1.3004% | $6.10 | $707,600 | +3.21% | |||
| 2018-09-04 | Chief Scientific Officer | 1,000 0.0038% | $5.00 | $5,000 | -30.64% | |||
| 2018-08-27 | Chief Scientific Officer | 1,000 0.0071% | $10.00 | $10,000 | -34.86% |
Insider Historical Profitability
| Dunne Michael W. | director | 113754 0.4134% | $1.77 | 8 | 1 | +124.28% |
| Ahrens Brenton Karl | director | 1733170 6.2988% | $1.77 | 1 | 0 | |
| CANAAN X L.P. | 1733170 6.2988% | $1.77 | 1 | 0 | ||
| HEALY JAMES | 1726514 6.2746% | $1.77 | 1 | 0 | ||
| Sofinnova Venture Partners IX, L.P. | 10 percent owner | 1226514 4.4575% | $1.77 | 1 | 2 |